Last reviewed · How we verify
pergolid
At a glance
| Generic name | pergolid |
|---|---|
| Sponsor | University Hospital Muenster |
| Target | 5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Parkinsonism
Common side effects
- Decreased appetite
- Lameness
- Diarrhea/Loose stool
- Colic
- Lethargy
- Abnormal Weight Loss
- Laminitis
- Heart murmur
- Tooth disorder
- Skin abscess
- Musculoskeletal pain
- Behavior change
Serious adverse events
- Death/Euthanasia
- Dystocia
- Seizure
- Ataxia
- Muscle tremors
- Thrombocytopenia
- Aggression
- Hyperactivity/Anxiety
Key clinical trials
- Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia (NA)
- Neuromodulation and Language Acquisition (Project Stage Ia) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pergolid CI brief — competitive landscape report
- pergolid updates RSS · CI watch RSS
- University Hospital Muenster portfolio CI